Current and Future Pathways in Aspergillus Diagnosis

0571234 - MBÚ 2024 RIV CH eng J - Článek v odborném periodiku
Dobiáš, R. - Stevens, D. A. - Havlíček, Vladimír
Current and Future Pathways in Aspergillus Diagnosis.
Antibiotics (Basel). Roč. 12, č. 2 (2023), č. článku 385. ISSN 2079-6382. E-ISSN 2079-6382
Grant CEP: GA ČR(CZ) GA22-06771S
Institucionální podpora: RVO:61388971
Klíčová slova: aspergillosis * galactomannan * beta-D-glucan * pcr * metagenomic next-generation sequencing * lateral flow * bronchoalveolar lavage fluid * serum assays * siderophore * metallophore
Obor OECD: Microbiology
Impakt faktor: 4.8, rok: 2022
Způsob publikování: Open access
https://www.mdpi.com/2079-6382/12/2/385

Aspergillus fumigatus has been designated by the World Health Organization as a critical priority fungal pathogen. Some commercially available diagnostics for many forms of aspergillosis rely on fungal metabolites. These encompass intracellular molecules, cell wall components, and extracellular secretomes. This review summarizes the shortcomings of antibody tests compared to tests of fungal products in body fluids and highlights the application of beta-D-glucan, galactomannan, and pentraxin 3 in bronchoalveolar lavage fluids. We also discuss the detection of nucleic acids and next-generation sequencing, along with newer studies on Aspergillus metallophores.
Trvalý link: https://hdl.handle.net/11104/0342506